Latest News

Latest News

Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.

In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

AI Transparency Gap in SaMD Regulation

AI Transparency Gap in SaMD Regulation

Artificial intelligence is no longer on the horizon of medical device regulation — it’s already on regulators’ desks. The FDA’s iterative guidance on AI/ML-based Software as a Medical Device (SaMD), the EU AI Act’s risk classification scheme, and Health Canada’s...

read more
Merck’s $6.7bn Terns Deal: A New Oral CML Treatment

Merck’s $6.7bn Terns Deal: A New Oral CML Treatment

Merck has completed its $6.7 billion acquisition of Terns Pharmaceuticals, gaining control of TERN-701, an investigational oral CML treatment that the pharmaceutical giant hopes will become a cornerstone of its expanding cancer portfolio. The deal, which closed on 5...

read more
Weekly News Roundup | 29 June 2026

Weekly News Roundup | 29 June 2026

Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...

read more
Clinical Trials Roundup | 26 June 2026

Clinical Trials Roundup | 26 June 2026

This week's clinical trial results for 26 June 2026 deliver a landmark psychiatric result, a major oncology setback, and a decisive blow to one of the most watched platforms in regenerative medicine. Definium Therapeutics' DT120 becomes the first lysergide therapy to...

read more
Beyond the Screen: Why Spinal Care Must Be Symptom-Led

Beyond the Screen: Why Spinal Care Must Be Symptom-Led

In an era dominated by high-resolution diagnostics, the field of spinal care faces a profound paradox: while our ability to visualise cellular and structural anatomy has never been more advanced, the clinical efficacy of spinal interventions has not risen in tandem....

read more
AI Transparency Gap in SaMD Regulation

AI Transparency Gap in SaMD Regulation

Artificial intelligence is no longer on the horizon of medical device regulation — it’s already on regulators’ desks. The FDA’s iterative guidance on AI/ML-based Software as a Medical Device (SaMD), the EU AI Act’s risk classification scheme, and Health Canada’s...

read more
Merck’s $6.7bn Terns Deal: A New Oral CML Treatment

Merck’s $6.7bn Terns Deal: A New Oral CML Treatment

Merck has completed its $6.7 billion acquisition of Terns Pharmaceuticals, gaining control of TERN-701, an investigational oral CML treatment that the pharmaceutical giant hopes will become a cornerstone of its expanding cancer portfolio. The deal, which closed on 5...

read more
Weekly News Roundup | 29 June 2026

Weekly News Roundup | 29 June 2026

Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...

read more
Clinical Trials Roundup | 26 June 2026

Clinical Trials Roundup | 26 June 2026

This week's clinical trial results for 26 June 2026 deliver a landmark psychiatric result, a major oncology setback, and a decisive blow to one of the most watched platforms in regenerative medicine. Definium Therapeutics' DT120 becomes the first lysergide therapy to...

read more
Beyond the Screen: Why Spinal Care Must Be Symptom-Led

Beyond the Screen: Why Spinal Care Must Be Symptom-Led

In an era dominated by high-resolution diagnostics, the field of spinal care faces a profound paradox: while our ability to visualise cellular and structural anatomy has never been more advanced, the clinical efficacy of spinal interventions has not risen in tandem....

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Finding AF Before It Strikes: The Case for National Screening

Finding AF Before It Strikes: The Case for National Screening

There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...

read more
CAR-T Therapy Reaches Solid Tumours for the First Time

CAR-T Therapy Reaches Solid Tumours for the First Time

China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...

read more
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic

Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic

The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...

read more
Weekly News Roundup | 22 June 2026

Weekly News Roundup | 22 June 2026

Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...

read more
Clinical Trials Roundup | 19 June 2026

Clinical Trials Roundup | 19 June 2026

The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...

read more

Further News

Rakuten Medical Appoints Former Takeda CEO Christophe Weber to Board

Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate US Growth and Oncology Innovation Enhanced Board and leadership team, including the appointment of a new Chief Medical Officer, strengthens governance,...

Why Hormone Health Knowledge Could Improve Female Staff Retention

The life sciences sector is built on evidence, innovation and better health outcomes. So why is women’s hormone health at work still so often treated as a peripheral issue, asks Sarah Davies, Managing Director of Balance@Work? Life sciences organisations spend their...

Tozorakimab COPD Trial Data Reach Below the Eosinophil Gate

AstraZeneca released the full tozorakimab COPD trial results on 8 September 2026. The company presented them as a late breaker at the European Respiratory Society Congress in Barcelona. The slot was the ALERT-2 plenary session. The New England Journal of Medicine...

Section 232 Pharma Tariffs: What Changes on 29 September

On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...

Regenerative Biologics and Biomaterials in Modern Aesthetic Surgery

The Shift Toward Regenerative Surgery When I trained, the reconstructive mindset in plastic surgery was largely mechanical. The goal was to restore form by moving tissue, removing what was damaged, or replacing what was missing, while accepting some degree of scarring...

Coming Off Weight Loss Injections: The Oral Maintenance Option

Orforglipron (Foundayo) is now available in the UK following The Medicines and Healthcare products Regulatory Agency (MHRA) approval on 10 August, making the UK the first European country to license it for weight management and type 2 diabetes. The first oral...

Camizestrant Approval Makes ctDNA Progression a Regulatory Endpoint

The camizestrant approval on 4 September 2026 makes ctDNA-detected progression a US regulatory trigger, months after the EU and UK cleared the drug.

    CBD Vaping: When Product Innovation Outpaces the Science

    Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...

    Neurodegeneration Pipeline 2026: Genetic Medicine Leads

    Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...

    The Future of Collagen Hydrogels in Regenerative Medicine

    Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...

    Novo Nordisk Halts Two IL-6 Heart Failure Trials for Futility

    Novo Nordisk has halted the HERMES and ATHENA IL-6 heart failure trials for futility, leaving ARTEMIS as the last ziltivekimab readout.

      After EMBRAZE: The Wider Race to Preserve Muscle During GLP-1 Treatment

      When results from the phase 2 EMBRAZE trial were published in Nature Medicine in June, apitegromab’s combination with tirzepatide became the most visible evidence yet that pharmacological muscle preservation during GLP-1 treatment might be achievable.¹ But...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.